What Rottendorf Pharma does

Rottendorf Pharma GmbH is a German contract development and manufacturing organization (CDMO) specializing exclusively in oral solid dosage forms. Founded in 1928 by Andreas J. Rottendorf and rebuilt in Ennigerloh after World War II, the company has spent 95+ years focused on formulation development, commercial bulk manufacturing, packaging (blister, cans, bottles), and analytical services for tablets and mini-tablets. It is 100% owned by the Rottendorf-Stiftung (Rottendorf Foundation), a structure established in 1971 that prevents the company from ever competing with its customers on product. The company is headquartered in Ennigerloh with a wholly-owned US sales subsidiary (Rottendorf Pharma Inc., relocated to Boston, MA in 2025), and a second production campus under construction in Oelde (operations planned for 2028) that will double long-term production capacity. Rottendorf holds full GMP compliance with extensive inspection histories from EMA, FDA, ANVISA and other authorities, is ISO 50001-certified since 2015, and is a member of the UN Global Compact.

The company generates revenue exclusively through B2B contract services for international pharmaceutical companies, operating as a custom-quoted professional services provider with no own-product portfolio. Its four core service lines — Development, Manufacturing, Packaging, and Analytics — are wrapped in three proprietary service concepts: Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI). The company attends major industry events (CPHI Worldwide, FIP, AAPS PharmSci 360, Bio Europe) and sells primarily through direct enterprise engagement with no public pricing or productized offering. Recent strategic actions include a 2026 partnership with Corealis Pharma for integrated early- to late-stage OSD development, the installation of new Gerteis dry granulation roller compactors in 2026, and the Oelde campus expansion. Awards include the CDMO Leadership Award Europe 2025 (Small Molecule Dosage Form, International) and Top Employer Germany 2025.

Rottendorf competes in the oral solid dose segment of the pharmaceutical CDMO market against larger multi-site players, with scale (501–1,000 employees), a single primary manufacturing footprint, and a foundation-owned capital base that supports long-horizon reinvestment rather than short-term shareholder returns. Its competitive position rests on regulatory track record, specialized OSD expertise, and the structural assurance that it will never commercialize competing products.

Name

Rottendorf Pharma

Legal name

Rottendorf Pharma GmbH

Website

https://rottendorf.com

Company type

Private

Founded year

1928

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Rottendorf Pharma is a German CDMO founded in 1928, specializing exclusively in oral solid dosage form development, manufacturing, packaging, and analytics for international pharmaceutical companies. It is wholly owned by the Rottendorf Foundation and operates from Ennigerloh with US presence in Boston.

Ownership category

akta.pro rank

Headquarters

HQ city

Ennigerloh

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Rottendorf Pharma operates exclusively as a CDMO, providing development, manufacturing, and packaging services for oral solid dosage forms to pharmaceutical companies. They do not market their own products and therefore never compete with their customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Rottendorf Pharma is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for oral solid dosage forms (tablets and mini-tablets) to international pharmaceutical companies. The service portfolio spans formulation and analytical development, commercial bulk manufacturing, packaging (blister, cans, bottles), and quality analytics, delivered under proprietary service concepts TPO©, TTM, and TSI. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Product overview

Rottendorf Pharma operates as a Contract Development and Manufacturing Organization (CDMO) specializing exclusively in oral solid dosage forms. The company offers an integrated service portfolio comprising four core capabilities: Development Services (formulation and analytical process development), Manufacturing Services (commercial bulk manufacturing), Packaging Services (blister, cans, bottles), and Analytics Services (quality testing). These core services are enhanced by three proprietary service concepts—Total Process Ownership (TPO©), Total Technology Mastering (TTM), and Total Supply Integrity (TSI)—which together provide comprehensive end-to-end support from early development through commercial supply. The company does not market its own pharmaceutical products and therefore never competes with its customers.

Differentiator

Problem solved

Functional benefit

Products and services

• Development Services Formulation and analytical process development for oral solid dosage forms, spanning pre-formulation through commercial supply, for pharmaceutical company clients seeking integrated OSD development support.
• Manufacturing Services Commercial bulk manufacturing of oral solid dosage forms including tablets, covering granulation, mixing, tableting, coating, and dragée production for pharmaceutical company clients under GMP.
• Packaging Services Primary packaging of oral solid dosage forms into blisters, cans, and bottles for pharmaceutical company clients.
• Analytics Services Quality analytics and analytical testing services for oral solid dosage forms, including chemical and physical analyses supporting development, manufacturing, and release for pharmaceutical company clients.

Quantifiable outcome

• CDMO Leadership Award Europe 2025 - Small Molecule Dosage Form, International (based on customer satisfaction surveys)
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Corealis PharmacoreStrategic or Co-development Partner · 11 February 2026Strategic partnership providing integrated early- to late-stage oral solid dosage (OSD) development services from pre-formulation through commercial supply. Combines Rottendorf's manufacturing and packaging expertise with Corealis's development capabilities for seamless OSD development and manufacturing.

Scale indicators6 records

Recent moves10 records

Expansion highlights4 records

Market position

Strengths1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/rottendorfpharma
• LinkedInlinkedin.com/company/rottendorf-pharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rottendorf Pharma